Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity

NCT04222920 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

OTHER: Dose reduction to 2mg/L
OTHER: Dose reduction to 5mg/L
DRUG: Adalimumab

Sponsor

Reade Rheumatology Research Institute

Collaborators

[object Object]
[object Object]